|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2007-9-24
|
|
pubmed:abstractText |
Data from the Intergroup Exemestane Study (IES) suggest that switching to the aromatase inhibitor, exemestane, after 2 to 3 years of tamoxifen therapy prolongs disease-free survival versus continuing on tamoxifen therapy. We sought to evaluate the cost-effectiveness of this management strategy.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1098-3015
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
10
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
367-76
|
|
pubmed:meshHeading |
pubmed-meshheading:17888101-Aged,
pubmed-meshheading:17888101-Androstadienes,
pubmed-meshheading:17888101-Antineoplastic Protocols,
pubmed-meshheading:17888101-Aromatase Inhibitors,
pubmed-meshheading:17888101-Breast Neoplasms,
pubmed-meshheading:17888101-Cost-Benefit Analysis,
pubmed-meshheading:17888101-Drug Administration Schedule,
pubmed-meshheading:17888101-Female,
pubmed-meshheading:17888101-Forecasting,
pubmed-meshheading:17888101-Humans,
pubmed-meshheading:17888101-Markov Chains,
pubmed-meshheading:17888101-Middle Aged,
pubmed-meshheading:17888101-Neoplasm Recurrence, Local,
pubmed-meshheading:17888101-Postmenopause,
pubmed-meshheading:17888101-Quality-Adjusted Life Years,
pubmed-meshheading:17888101-SEER Program,
pubmed-meshheading:17888101-Selective Estrogen Receptor Modulators,
pubmed-meshheading:17888101-Tamoxifen
|
|
pubmed:articleTitle |
Cost-effectiveness of switching to exemestane after 2 to 3 years of therapy with tamoxifen in postmenopausal women with early-stage breast cancer.
|
|
pubmed:affiliation |
i3 Innovus, Medford, MA 02155, USA. david.thompson@i3innovus.com
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
